-
-
-
Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit
2025-04-01
On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”) held its 2024 annual results presentation in Shanghai. The results presentation was attended by Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu and Xu Xiaoliang, Co-CEOs of Fosun International, Gong Ping, CFO of Fosun International, and a number of institutional investors and analysts.
-
-
-
-
Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
2025-03-30
(Hong Kong, Shanghai, 30 March 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2024 (the “Reporting Period”).
-
-
-
-
Fosun International Successfully Refinanced USD 870 Million Offshore Syndicated Loan
2025-03-28
Fosun International (HKEX stock code: 00656, hereinafter referred to as "Fosun International", "Fosun", or the "Company") has successfully completed the refinancing of a USD 870 million equivalent syndicated loan due on March 28, 2025. Of this amount, USD 675 million equivalent was secured through a newly arranged syndicated loan. Consistent with the Company’s past practices, the new syndicated loan includes a greenshoe option, allowing additional banks to participate.
-
-
-
-
Fosun Pharma Announces 2024 Annual Results: Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY
2025-03-25
(March 25, 2025, Shanghai, China) On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK),a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 (“the Reporting Period”).
-
-
-
-
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
2025-03-24
Shanghai, China, March 24, 2025 – Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius’ total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached RMB820.5 million, a 50.3% YoY growth, with a net profit margin of 14.3%, up by 41.6% YoY. This marks Henlius' second consecutive year of full-year profitability following its first profitable year in 2023. The increasing commercial sales of core products have been a key driver of profitability, with total product sales revenue reaching approximately RMB4.9335 billion, an increase of 8.3% YoY. Additionally, the company’s annual R&D expenditure reached RMB1.8405 billion, representing an increase of 28.4% YoY.
-
-
-
-
Sisram Medical Announces 2024 Annual Results New product launches drive double-digit growth in key markets and deliver market outperformance amid economic challenges
2025-03-19
Hong Kong, March 19, 2025 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK; together with its subsidiaries collectively referred to as the “Group”), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), Injectables, alongside other complementary offerings, announced its audited consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).
-
-
-
-
Fosun successfully concluded 2024 sustainability-linked syndicated loan through greenshoe, final facility size reaching USD888 million with 25 participating banks
2024-10-02Fosun
(2 October 2024, Hong Kong) Fosun International Limited (HKEX stock code: 00656, “FosunInternational”, “Fosun” or “the Company”) has successfully completed asustainability-linked syndicated loan amounting to USD888 million. The loan wasinitially launched earlier this year in May with first close of USD603 million,followed by Greenshoe accessions. The final size r
-
-
-
-
Fosun International: Total Revenue for the First Half of 2024 Reaches RMB97.84 Billion, Industrial Operation Profit Amounts to RMB 3.47 Billion
2024-08-28
Fosun International Announces 2024 Interim Results: Powered by Core Strengths, Focus on Core Businesses and Reinforce Organic Growth Momentum 2024 Interim Results Highlights:·Total revenue maintained growth, reaching RMB97.84 billion;·Industrial operation profit maintained growth, reaching RMB3.47 billion;·Continued focus on core businesses, with the four core subsi
-
-
-
-
Fosun Pharma Announces 2024 Interim Results Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen
2024-08-27
(August 27, 2024, Shanghai China) On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK),announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% Y
-